Non vitamin-K-antagonist oral anticoagulants (NOACs) have emerged as preferred treatment over vitamin K antagonists (VKAs) for the prevention of stroke in patients with nonvalvular atrial fibrillation (AF)[1, 2]. However, prospective observational data on clinical NOAC use during cardiovascular interventions are limited.
